Sun Pharma records net profit of Rs. 44 crore

SP Tulsian of sptulsian.com is of the view that one can go long in Dena Bank with a target of Rs 97 and buy Sun Pharma Advanced Research with a target of Rs 169.

VK Sharma, Head Private Broking Wealth Management at HDFC Securities is of the view that Sun Pharma Advanced Research Company can give better returns than Sun Pharmaceutical Industries.

Sun Pharma Advanced Research Company is currently trading at Rs. 107.95, up by 1.60 points or 1.50% from its previous closing of Rs. 106.35 on the BSE. The scrip opened at Rs. 107.50 and has touched a high and low of Rs. 108.80 and Rs. 106.80 ...

Aashish Tater, Head of Research, Fortunewizard.com feels that there is lot of money that can be made in Sun Pharma Advance Research Company.

Sun Pharma Advanced Research Company (SPARC) has surged 5% to Rs 151, extending its previous day’s 15% rally, after reporting net profit of Rs 44 crore for the fourth quarter ended March 31, 2013 on back of healthy growth in operational income.

NEW YORK, Jan. 30, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: ...

EnWave Corporation (EnWave) is a technology company that develops commercial applications for its proprietary Radiant Energy Vacuum (REV) technology in food and biomedical sectors. The company has six existing platforms developed on REV, namely, ...

K Subramanayam, AVP - Institutional Research at Asit C Mehta Securities spoke to Surabhi Roy on his views on Indian markets in the near-term and outlook going ahead. Markets have been consolidating after a sharp up move last week. What strategy ...

Although global economic recovery still remains fragile and the road back to normalcy is a long and difficult one, the fortunes of India's pharmaceutical industry remain upbeat. Whereas the financial year gone by has been a dismal one for companies ...